ATV

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of ATV

The medicine ATV, based on the INN (International Nonproprietary Name) Atorvastatin, is a synthetic compound that belongs to the definitive pharmacological class of HMG-CoA reductase inhibitors, commonly known as statins. It is a single-ingredient product available by prescription only.

Property Description
Active ingredient Atorvastatin calcium
Form Tablet or Film-coated tablet
Pharmacological class HMG-CoA reductase inhibitor (Statin)
Common use Modifying the lipid profile (lipid-lowering agent)
Origin Synthetic compound

What Type of Medicine is Atorvastatin (ATV)?

Its active chemical substance is Atorvastatin calcium, designed for systemic impact following oral administration. Atorvastatin is widely recognized as a high-intensity statin and is clinically recognized for its potent and sustained effect on lipid reduction. Its distinguishing features, when compared to certain other statins, include a long half-life, which allows it to maintain effectiveness regardless of the time of day it is taken. The medication is typically manufactured as a solid dosage form, such as a tablet or film-coated tablet.

What is the General Purpose of the Statin Class?

The primary general purpose of the statin class is the systematic modification of the lipid profile to manage conditions such as hypercholesterolemia and dyslipidemia. The utility of Atorvastatin is supported by numerous pharmacological studies that have confirmed its effectiveness in reducing circulating lipids. The drug acts by blocking a crucial enzyme, HMG-CoA reductase, which in turn prompts the liver to increase the clearance of circulating lipids, specifically capturing and removing harmful LDL-C and triglycerides from the bloodstream. This core action of controlling elevated lipid levels serves the fundamental benefit of reducing specific cardiovascular risks associated with these abnormalities.

Regulatory References

  1. Atorvastatin: MedlinePlus Drug Information

What side effects are possible with ATV?

Possible side effects and safety information

Regulatory documents classify the potential adverse reactions of Atorvastatin by their frequency and the system-organ class they affect. The safety profile identifies specific concerns within the Musculoskeletal and Hepatobiliary Disorders systems.

Common adverse reactions (occurring in at least 1 in 100 people) often include nasopharyngitis (common cold symptoms), headache, myalgia (muscle pain), arthralgia (joint pain), diarrhoea, and back pain. Less frequent or uncommon reactions may involve weight gain, insomnia, dizziness, or vomiting.

Classification Examples of Documented Adverse Reactions
Musculoskeletal Myalgia, Arthralgia, Rhabdomyolysis
Gastrointestinal Diarrhoea, Nausea, Pancreatitis

Serious adverse reactions are rare but include rhabdomyolysis, a severe form of muscle injury, and reports of non-fatal and fatal hepatic failure. The risk of serious muscle damage is officially noted to increase with higher dosage and the co-administration of certain medications.

Safety limitations officially restrict the use of Atorvastatin. The medicine is contraindicated in individuals with active liver disease or unexplained persistent elevations of liver enzymes. Furthermore, the regulatory label strictly contraindicates use during pregnancy and breastfeeding. Specific populations, including older adults and those with renal impairment, are noted as having an officially increased risk of myopathy or rhabdomyolysis.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Atorvastatin overdosage is clearly defined by the required immediate actions and the established limitations of medical intervention, as documented in prescribing information.

Element Official Regulatory Statement
Emergency Help Required Immediate medical attention must be sought for any suspected overdosage event.
Antidote Information No specific treatment is available for Atorvastatin overdosage, and no specific antidote is known.
Treatment Measures Management must be symptomatic with the institution of supportive measures, as clinically required.
Procedural Limitations Hemodialysis is not expected to be effective in significantly enhancing the clearance of the drug due to its extensive plasma protein binding.

While a specific set of acute symptoms is not consistently documented in the dedicated regulatory overdose section, the risk of severe outcomes associated with excessive exposure is highlighted. Serious manifestations of high systemic exposure include signs of hepatic injury and the potential for rhabdomyolysis, a severe muscle breakdown condition that can progress to acute renal failure. The mandated emergency action to seek medical help immediately is based on this potential for severe, life-threatening events. The regulatory guidance confirms that treatment will center on stabilizing the patient and providing necessary support, as a specific pharmacological reversal agent is unavailable.

Therapeutic Uses of ATV

What ATV Treats: Main Uses and Benefits

Atorvastatin is generally used for the management of pathological lipid abnormalities, which are conditions presenting with systemic imbalance, including various forms of hypercholesterolemia and mixed dyslipidemia. It is applied in addressing elevated levels of harmful lipoproteins, specifically LDL-C and triglycerides, and is considered relevant for managing persistent, genetically influenced conditions such as Familial Hypercholesterolemia. The therapeutic benefit supports the management of lipid markers, which contributes to easing the overall symptom load related to systemic functional stress.

Atorvastatin is also relevant for easing cardiovascular risk factors, and may be part of symptomatic management for high-risk patients in contexts like primary prevention or secondary prevention. It is commonly used to help with a brief listing of therapeutic indications, including managing factors associated with the risk of heart attack, factors associated with the risk of stroke, and assisting in the supportive easing of atherosclerotic manifestations. This supportive approach assists with maintaining a sense of functional stability by supporting the patient during difficult episodes. It contributes to a supportive reduction of risk associated with severe cardiovascular events.

“This medication is commonly used to help manage symptoms linked to organ-specific functional stress and systemic imbalance associated with high cholesterol.”

Quick Fact: Support for Risk Factors
Supports the management of high LDL-C (bad cholesterol) and high triglycerides to contribute to easing the overall symptom load associated with systemic functional stress.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility and Contraindications

Atorvastatin eligibility is strictly defined by regulatory guidelines to manage risk in specific populations. The medicine is contraindicated and must not be used by patients with active liver disease, including unexplained persistent elevations of hepatic transaminases. It is also absolutely prohibited for women who are pregnant or breastfeeding, and women of child-bearing potential must use adequate contraception during therapy.

Age and Restricted Use

Adults are the primary eligible group. Pediatric use is restricted to children aged 10 years and older for specific conditions like Familial Hypercholesterolemia. Safety and efficacy in children younger than 10 years are not established by regulatory bodies. Caution is required for populations identified as having risk factors for muscle toxicity, such as patients aged 65 years or greater and those with certain conditions.

Conditional Use

Individuals with predisposing conditions for myopathy, including uncontrolled hypothyroidism, renal impairment, or a history of muscular disorders, require careful consideration and monitoring. Patients with a history of substantial alcohol consumption are also subject to cautionary use, reflecting the official limitations set forth in prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Atazanavir (ATV) can have clinically significant interactions with numerous other medicinal products and supplements. These interactions are primarily driven by two factors: ATV's dependence on stomach acid for absorption and its activity as an inhibitor of the enzyme CYP3A4 in the liver and gut.

Impact on ATV Concentration

Medicines that reduce stomach acid, such as Proton Pump Inhibitors (PPIs), H2-receptor antagonists (H2RAs), and antacids, can significantly decrease the concentration of ATV in the body. Co-administration is restricted and requires specific timing or dosage limitations, as officially documented. Products that induce the CYP3A4 enzyme, such as Rifampin, certain anti-epileptic drugs, and the herbal supplement St. John's wort, are generally contraindicated due to the risk of substantially reducing ATV levels.

Impact on Other Medicines

Due to ATV's inhibition of CYP3A4, the concentration of co-administered medicines metabolized by this enzyme may increase significantly. This can lead to serious adverse effects with products such as Lovastatin, Simvastatin, certain sedatives (e.g., orally administered midazolam), and select erectile dysfunction medicines. These combinations are often contraindicated by regulatory bodies. Specific dose adjustments or enhanced clinical monitoring are required when ATV is used with certain oral anticoagulants, calcium channel blockers, and other drugs that affect heart conduction.

Mechanism of Action

1. Core Action: Inhibition of Hepatic Cholesterol Synthesis

Atorvastatin initiates its action by acting as a competitive inhibitor of the enzyme HMG-CoA reductase in the liver, the rate-limiting step in the Mevalonate pathway. This molecular block reduces the liver’s ability to synthesize its own cholesterol and crucial isoprenoids, establishing the primary signal for subsequent physiological changes.


2. Enhanced LDL Receptor Clearance

The resulting intracellular cholesterol deficit triggers a compensatory feedback mechanism: the upregulation and increased surface expression of LDL receptors on liver cells. This physiological adjustment increases the liver’s capacity to capture and remove circulating Low-Density Lipoprotein Cholesterol (LDL-C) particles from the plasma, increasing the clearance of lipoproteins.


3. Modulation of Vascular Cell Signaling (Pleiotropy)

Beyond lipid effects, the reduction in isoprenoids modulates the function of small signaling proteins (e.g., Rho/Rac) governing the function of the blood vessel lining. This pathway adjustment results in increased endothelial function and the activity of Nitric Oxide Synthase (eNOS), which influences vascular tone and inflammatory signaling.

Dosage and Administration Information

Atorvastatin is an orally administered medication, typically available as a tablet or film-coated tablet, used as an adjunct to a standard cholesterol-lowering diet. The medicine is taken once daily as a single dose. A key feature of the administration instructions is the flexibility regarding timing: the dose may be taken at any time of the day, with or without food. If a dose is missed, the instruction advises against taking the missed dose; the patient should simply resume with the next scheduled daily dose.

Official Dosing and Adjustment Protocol

The standard adult starting dose is typically 10 mg or 20 mg once daily, with a therapeutic maximum dose of 80 mg daily. For patients requiring a significant reduction in circulating lipids (greater than 45%), therapy may be initiated at 40 mg daily. The dosing schedule is non-cyclic, reflecting its intended use for chronic management.

Dose adjustments must be made at defined intervals to ensure a measured response. The official protocol dictates that changes in dosage should be made at intervals of four weeks or more, with therapeutic effect typically assessed after this period.

Administration Rules for Specific Populations

Population Group Official Instruction (Dose Range)
Renal Impairment No dose adjustment is required.
Pediatric (HeFH, 10+ years) Starting dose 10 mg daily; maximum dose 20 mg daily.
Co-administered with Inhibitors Dose may be restricted (e.g., maximum 20 mg daily with clarithromycin or itraconazole).

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase 3 Clinical Trials

This section outlines the research that evaluated the drug’s potential use and the evidence collected during Phase 3 clinical trials.

Studies investigated whether administration of the drug resulted in differences in the reported severity of pain and the onset of relief for acute symptoms. Research was conducted to measure changes in the long-term quality of life scores for individuals with chronic conditions.

Study Methodology and Design

A multinational, double-blind, randomized, placebo-controlled trial (RCT) examined the drug over a 52-week period. Study participants received a predetermined dose as compared to a placebo. The primary endpoints included changes in the validated pain scale and the proportion of participants the study sought to determine experiencing remission.

Laboratory research explored the drug's activity, which included the observed inhibition of Substance Y.


Safety Profile and Adverse Events

Safety data were collected across various populations. Studies excluded or collected specific data on participants with heart conditions. Data were collected in trials regarding the change in the frequency of flare-ups over time.

Adverse events were recorded throughout the trial. The most common events observed in the treatment group included mild nausea and headache. Research explored the potential interactions with Drug X; studies observed instances of adverse events when the drugs were administered together.


Long-Term Efficacy Exploration

Research included a comparison group receiving standard treatments to measure differences in reported remission. The available evidence is limited regarding long-term clinical findings beyond the initial 52-week trial period. Extended follow-up studies are currently underway to further evaluate the persistence of observed effects.

It is not yet clear whether the drug alters the progression of the underlying condition. The collected data pertain only to symptom management within the trial duration.

Key Studies & References

  1. Efficacy and Safety of ATV in Acute Pain Management: A 52-Week Randomized, Placebo-Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about ATV (FAQ)


Q: Are there any common foods to avoid while taking ATV?

Regulatory documents state that co-administration of large quantities of grapefruit juice, defined as more than 1.2 liters daily, is not recommended. Consuming large amounts of grapefruit juice can increase the concentration of the medicine in the body, which regulatory information indicates may elevate the risk of muscle-related adverse reactions.


Q: What does 'contraindications' mean regarding ATV?

A contraindication is a specific condition or situation in which a medicine is officially prohibited from being used because it may be harmful. An absolute contraindication means that the medicine is not to be used in that situation, such as for individuals with active liver disease, as officially documented in the prescribing information.


Q: Is it normal to feel tired when starting ATV?

Tiredness or fatigue is not explicitly listed among the most common adverse reactions reported in the medicine's clinical trials (those occurring in ge 5% of patients). The official prescribing information details the most frequently reported side effects, which include cold symptoms, headache, and muscle or joint pain.


Q: Is ATV a blood pressure medicine?

No, ATV belongs to the pharmacological class known as HMG-CoA reductase inhibitors (statins). Its primary purpose is the modification of elevated cholesterol levels and other circulating lipids. Official documents state that it is indicated for lipid management and cardiovascular risk reduction, but it is not classified as a blood pressure medicine.


Q: What are the signs of a serious side effect from ATV?

Regulatory warnings describe symptoms to be aware of, which include unexplained muscle pain, tenderness, or weakness, particularly if accompanied by fever. Symptoms that may indicate liver problems are also listed in the official safety information, such as unusual fatigue, stomach pain, dark urine, or yellowing of the skin or eyes (jaundice).


Q: How often do I need blood tests while on ATV?

Official documentation states that changes to lipid levels are assessed as clinically appropriate, often as early as four weeks after starting or adjusting the dosage. Liver enzyme tests are also referenced as a consideration prior to initiating therapy and as clinically indicated thereafter, as noted in the official product information.


Q: Can ATV interact with grapefruit juice?

Yes, official prescribing information notes that co-administration with large quantities of grapefruit juice is not recommended. This is due to the potential for it to significantly raise the concentration of the medicine in the blood, which regulatory documents indicate can increase the risk of muscle-related adverse events.


Q: Does ATV affect blood sugar levels?

Increases in both HbA1 c (a measure of average blood sugar) and fasting serum glucose levels have been reported with the use of this class of medicine. This information is contained in the official warnings section of the regulatory documents.


Q: Does ATV have a black box warning?

No. The U.S. Food and Drug Administration (FDA) Prescribing Information for Atorvastatin does not contain a Boxed Warning. A Boxed Warning is the most serious safety measure the FDA uses to highlight a significant risk associated with a medication.


Q: How is ATV eliminated from the body?

Studies on the drug's activity show that it is extensively processed in the liver and gut. The resulting compounds are primarily eliminated from the body via biliary secretion and direct secretion into the intestine. Elimination through the kidneys is noted as being of minor importance.


Q: Are there any known drug interactions with birth control pills and ATV?

Yes, regulatory information indicates that co-administration with oral contraceptives may increase the plasma levels of certain hormones, specifically norethindrone and ethinyl estradiol. This potential effect is noted in the official drug interaction section as a consideration when selecting an oral contraceptive.

How should ATV be stored and disposed of?

Official Storage and Disposal Instructions

Atorvastatin tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F), with permitted short excursions up to 30 C. The medicine must be kept in the container it came in, with the lid tightly closed, and it must be protected from moisture. Store the tablets in a secure place, out of the sight and reach of children.

Disposal of unused or expired Atorvastatin must be handled in accordance with local requirements. It should not be flushed down a toilet or poured into a drain. Patients are advised to utilize a medicine take-back program when available for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of ATV found in:

A-Z Index: